Last update 19 Dec 2024
1200 Pharma LLC

1200 Pharma LLC

Startups
|
Holding Company|
2017|
California, United States
|
10-50
|
www.1200pharma.com

Overview

Basic Info

Introduction
1200 Pharma employs cutting-edge medicinal chemistry technology from Caltech and exclusive biomarker-driven assays from UCLA to significantly reduce the time it takes to discover and approve drugs in clinical trials.

Tags

Neoplasms
Chemical drugs
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms3
Top 5 Drug TypeCount
Chemical drugs2
Small molecule drug1
Top 5 TargetCount
CDK4 x CDK61
PRMT5(Protein arginine methyltransferase 5)1
KRAS G12C(GTPase KRas G12C)1

Related

3
Drugs associated with 1200 Pharma LLC
UCT-03-008
Target
CDK4 x CDK6
Mechanism
CDK4 inhibitors [+1]
Active Org.
1200 Pharma LLC1200 Pharma LLCStartup
Originator Org.
1200 Pharma LLC1200 Pharma LLCStartup
Active Indication
Advanced Malignant Solid Neoplasm
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
UCT-001024
Target
KRAS G12C
Mechanism
KRAS G12C inhibitors
Active Org.
1200 Pharma LLC1200 Pharma LLCStartup
Originator Org.
1200 Pharma LLC1200 Pharma LLCStartup
Active Indication
Neoplasms
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
UCT-000445
Target
PRMT5
Mechanism
PRMT5 inhibitors
Active Org.
University of California, Los AngelesUniversity of California, Los Angeles [+1]
Originator Org.
1200 Pharma LLC1200 Pharma LLCStartup [+1]
Active Indication
Solid tumor
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
2
Clinical Trials associated with 1200 Pharma LLC
NCT05103046 / RecruitingPhase 1
A Phase 1, First in Human, Dose-Escalation Study of UCT-03-008 in Participants With Advanced Solid Tumors
NCT04761601 / TerminatedPhase 1
A Phase 1, First in Human, Dose-Escalation Study of UCT-01-097 in Participants With Advanced Solid Tumors
100 Clinical Results associated with 1200 Pharma LLC
Login to view more data
0 Patents (Medical) associated with 1200 Pharma LLC
Login to view more data
100 Deals associated with 1200 Pharma LLC
Login to view more data
100 Translational Medicine associated with 1200 Pharma LLC
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
2
1
Phase 1
Other
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
UCT-03-008
 ( CDK4 x CDK6 )		Advanced Malignant Solid Neoplasm
More
Phase 1
UCT-000445
 ( PRMT5 )		Solid tumor
More
Preclinical
UCT-001024
 ( KRAS G12C )		Neoplasms
More
Preclinical
UCT-01-097
 ( ERK1 x ERK2 )		Advanced Malignant Solid Neoplasm
More
Discontinued
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free